A citation-based method for searching scientific literature

Samuel J P Malkin, Monika Russel-Szymczyk, Girtel Liidemann, Vallo Volke, Barnaby Hunt. Diabetes Ther 2019
Times Cited: 7







List of co-cited articles
57 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Validation of the IMS CORE Diabetes Model.
Phil McEwan, Volker Foos, James L Palmer, Mark Lamotte, Adam Lloyd, David Grant. Value Health 2014
116
85

Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Adie Viljoen, Christina S Hoxer, Pierre Johansen, Samuel Malkin, Barnaby Hunt, Stephen C Bain. Diabetes Obes Metab 2019
20
85

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Andrew J Palmer, Stéphane Roze, William J Valentine, Michael E Minshall, Volker Foos, Francesco M Lurati, Morten Lammert, Giatgen A Spinas. Curr Med Res Opin 2004
350
85



Effect of a multifactorial intervention on mortality in type 2 diabetes.
Peter Gaede, Henrik Lund-Andersen, Hans-Henrik Parving, Oluf Pedersen. N Engl J Med 2008
71

Validation of the CORE Diabetes Model against epidemiological and clinical studies.
Andrew J Palmer, Stéphane Roze, William J Valentine, Michael E Minshall, Volker Foos, Francesco M Lurati, Morten Lammert, Giatgen A Spinas. Curr Med Res Opin 2004
210
71

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
71

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.
Marc Evans, Kamlesh Khunti, Muhammad Mamdani, Claus B Galbo-Jørgensen, Jens Gundgaard, Mette Bøgelund, Stewart Harris. Health Qual Life Outcomes 2013
109
71

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt, Samuel Joseph Paul Malkin. Diabetes Ther 2019
10
71

Review of utility values for economic modeling in type 2 diabetes.
Amélie Beaudet, John Clegg, Per-Olof Thuresson, Adam Lloyd, Phil McEwan. Value Health 2014
96
57

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
57

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
57

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.
Faramarz Ismail-Beigi, Timothy Craven, Mary Ann Banerji, Jan Basile, Jorge Calles, Robert M Cohen, Robert Cuddihy, William C Cushman, Saul Genuth, Richard H Grimm,[...]. Lancet 2010
818
57

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
57

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
225
42

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Pierre Johansen, Jonas Håkan-Bloch, Aiden R Liu, Peter G Bech, Sofie Persson, Lawrence A Leiter. Pharmacoecon Open 2019
8
42


Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.
Simon J Griffin, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy E H M Rutten, Annelli Sandbæk, Stephen J Sharp, Rebecca K Simmons, Maureen van den Donk, Nicholas J Wareham,[...]. Lancet 2011
303
42


Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.
Kamlesh Khunti, Marilia B Gomes, Stuart Pocock, Marina V Shestakova, Stéphane Pintat, Peter Fenici, Niklas Hammar, Jesús Medina. Diabetes Obes Metab 2018
114
42

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Samuel J P Malkin, Monika Russel-Szymczyk, Marek Psota, Lucia Hlavinkova, Barnaby Hunt. Adv Ther 2019
4
75


10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
42

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
541
28

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.
Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Nana Kragh, Gabriela Vega-Hernandez, Johannes Pöhlmann, William J Valentine, Barnaby Hunt. Diabetes Ther 2017
12
28

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen, Rory J McCrimmon. Lancet Diabetes Endocrinol 2019
63
28

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
P M Kearney, L Blackwell, R Collins, A Keech, J Simes, R Peto, J Armitage, C Baigent. Lancet 2008
28

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
634
28


Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood. J Clin Endocrinol Metab 2018
97
28


Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
178
28



Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
28

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher Sorli, Shin-Ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Stephen C Bain. Lancet Diabetes Endocrinol 2017
177
28

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
28

The current total economic burden of diabetes mellitus in the Netherlands.
M L Peters, E L Huisman, M Schoonen, B H R Wolffenbuttel. Neth J Med 2017
19
28

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.
Craig J Currie, Christopher Ll Morgan, Chris D Poole, Peter Sharplin, Morten Lammert, Phil McEwan. Curr Med Res Opin 2006
188
28

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Richard Pratley, Aslam Amod, Søren Tetens Hoff, Takashi Kadowaki, Ildiko Lingvay, Michael Nauck, Karen Boje Pedersen, Trine Saugstrup, Juris J Meier. Lancet 2019
153
28

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example.
Vanita R Aroda, Trine Saugstrup, John B Buse, Morten Donsmark, Jeppe Zacho, Melanie J Davies. Diabetes Obes Metab 2019
36
28



Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
K Khunti, A Nikolajsen, B L Thorsted, M Andersen, M J Davies, S K Paul. Diabetes Obes Metab 2016
155
28

Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries.
Jørgen T Lauridsen, Jonas Lønborg, Jens Gundgaard, Henrik Holm Jensen. Qual Life Res 2014
28
28

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya. Diabetes Care 2019
99
28


Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Julio Rosenstock, Dale Allison, Andreas L Birkenfeld, Thalia Marie Blicher, Srikanth Deenadayalan, Jacob Bonde Jacobsen, Pierre Serusclat, Rafael Violante, Hirotaka Watada, Melanie Davies. JAMA 2019
117
28

Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis.
Jean-Blaise Wasserfallen, Georges Halabi, Patrick Saudan, Thomas Perneger, Harold I Feldman, Pierre-Yves Martin, Jean-Pierre Wauters. Nephrol Dial Transplant 2004
83
28


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.